Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 11/20 | 0.44 |
| ▸ | BCL2 | P10415 | 10/20 | 0.44 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501700 | 0.92 | MCL1 (0.40) | MCL1BCL2ALOX5APPPARG | |
| SCHEMBL6496934 | 0.91 | MCL1 (0.54) | MCL1BCL2PIK3C2B | |
| SCHEMBL7194322 | 0.91 | BCL2 (0.48) | MCL1BCL2PIK3C2BMRGPRX4 | |
| SCHEMBL6492244 | 0.90 | PPARG (0.46) | MCL1BCL2ALOX5APPPARG | |
| SCHEMBL6500949 | 0.88 | BCL2 (0.54) | MCL1BCL2MRGPRX4 | |
| SCHEMBL6490840 | 0.86 | BCL2 (0.46) | MCL1BCL2ALOX5APPPARG | |
| SCHEMBL6488344 | 0.86 | MCL1 (0.47) | MCL1PPARG | |
| SCHEMBL6500643 | 0.85 | ALOX5AP (0.40) | MCL1BCL2PIK3C2BALOX5AP | |
| SCHEMBL6499263 | 0.85 | ALOX5AP (0.41) | MCL1BCL2ALOX5APPPARG | |
| SCHEMBL6500130 | 0.84 | DCTPP1 (0.47) | MCL1BCL2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | MCL1 806/4885BCL2 774/4885PIK3C2B 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.